Connect with us

Public Companies

News You Might Have Missed: Jan 11th, 2022

The article News You Might Have Missed: Jan 11th, 2022 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup…

Published

on

The article News You Might Have Missed: Jan 11th, 2022 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.

It was a busy week with lots of news, have a look and see you next week for another update.

 

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

Wesana is pleased to announce that the U.S Food and Drug Administration (U.S. FDA) granted the Company’s request for a pre-IND (Investigational New Drug) meeting to discuss the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder (MDD).

Ketamine One Appoints Two New Members to Its Medical Advisory Board

The company is pleased to announce that Corey Hilmas, MD, PhD has been appointed to the Company’s Medical Advisory Board (“MAB”) and will be assuming the role of Interim Chair of the MAB. Additionally, Brigadier General (Ret.) Loree K. Sutton, MD, has also been appointed to the MAB.

MindMed Successfully Completes Phase 1 Trial of 18-MC

MindMed announced the completion of its Phase 1 clinical trial of 18-MC, the Company’s non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder. The trial was completed in December 2021 with topline results expected in early 2022.

Field Trip to Apply on Behalf of Patients for Psychedelic Access Program

The announcement follows amendments to the SAP announced in the Canada Gazette on January 5, 2022, which have enabled physicians in Canada to make applications to Health Canada for access to “restricted drugs”, including psilocybin and MDMA.

Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee

“We are thrilled with the progress that was made by the Company in 2021 and are excited to kick-off EBRX-101 later this quarter,” says Timothy Ko, CEO of Entheon. “This human trial has been designed to be one of the most comprehensive studies of DMT to date and will serve as a benchmark for further investigation into DMT as a treatment for addiction disorders.”

Braxia Scientific Announces CAD$3 Million Private Placement with Institutional Investors

The net proceeds of the Private Placement will be used by the Company for the expansion of clinics, certain strategic investments and general working capital to deliver improved patient outcomes.

Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed

Read More

Trending